Adenosine Triphosphate

Adenosine Triphosphate

SCHEMBL924732

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Mn+4]

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 8/20 0.79
P2RY11 Q96G91 3/20 0.79
ENPP1 P22413 2/20 0.76
BLM P54132 2/20 0.75
TSHR P16473 1/20 0.75
KDM4E B2RXH2 1/20 0.75
LMNA P02545 1/20 0.75
P2RY2 P41231 3/20 0.73
SRC P12931 2/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
P2RX1 P51575 1/20 0.73
P2RX3 P56373 1/20 0.73
P2RX4 Q99571 1/20 0.73
P2RX2 Q9UBL9 1/20 0.73
ALDH1A1 P00352 1/20 0.73
TRPM2 O94759 2/20 0.73
DNPH1 O43598 1/20 0.73
PRKAB2 O43741 1/20 0.73
LDHA P00338 1/20 0.73
ADRB2 P07550 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine Triphosphate SCHEMBL29905572 0.99 P2RY1 (0.80) P2RY1P2RY11ENPP1BLMTSHR
Adenosine Triphosphate SCHEMBL29576424 0.99 P2RY1 (0.80) P2RY1P2RY11ENPP1BLMTSHR
Adenosine Triphosphate SCHEMBL193646 0.99 P2RY1 (0.80) P2RY1P2RY11ENPP1BLMTSHR
Adenosine Triphosphate SCHEMBL29796747 0.98 P2RY1 (0.79) P2RY1P2RY11ENPP1BLMTSHR
Adenosine Triphosphate SCHEMBL3134374 0.98 P2RY1 (0.79) P2RY1P2RY11ENPP1BLMTSHR
Adenosine Triphosphate SCHEMBL29670849 0.98 P2RY1 (0.79) P2RY1P2RY11ENPP1BLMTSHR
Adenosine Triphosphate SCHEMBL31149196 0.98 P2RY1 (0.79) P2RY1P2RY11ENPP1BLMTSHR
Adenosine Triphosphate SCHEMBL29480645 0.98 P2RY1 (0.79) P2RY1P2RY11ENPP1BLMTSHR
Adenosine Triphosphate SCHEMBL30606657 0.98 P2RY1 (0.79) P2RY1P2RY11ENPP1BLMTSHR
Lithium Ion SCHEMBL28406951 0.98 P2RY1 (0.79) P2RY1P2RY11ENPP1BLMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120171156-A1 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LTD. (GB) 2012-07-05 US claimed
EP-2442873-A2 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES Hds Limited (GB) 2012-04-25 EP claimed
WO-2010146142-A9 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LIMITED (GB) 2011-06-16 WO claimed
WO-2010146142-A2 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LIMITED (GB) 2010-12-23 WO claimed
US-7597879-B2 Sunscreen safety and efficacy enhancement BIODERM RESEARCH (US) 2009-10-06 US claimed
US-20070189992-A1 Sunscreen Safety and Efficacy Enhancement with Manganese Complexes via Urocanate Pathway BIODERM RESEARCH (US) 2007-08-16 US claimed
US-20060127430-A1 Controlled-Release of Cosmetic and Pharmaceutical Agents via Osmotic Nano-Diffusion from Zeolite Cage Complexes BIODERM RESEARCH (US) 2006-06-15 US claimed
WO-2026104886-A1 METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY 유엔케이코리아 주식회사 2026-05-21 WO disclosed
US-12350352-B2 Composition for surface modification LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2025-07-08 US disclosed
EP-4464307-A1 COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME MPLUS COSMETICS S.R.L. (IT) 2024-11-20 EP disclosed
US-20240374498-A1 COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME MPLUS COSMETICS S.R.L. (IT) 2024-11-14 US disclosed
EP-3342395-B1 COMPOSITION FOR HAIR SURFACE MODIFICATION LG HOUSEHOLD & HEALTH CARE LTD (KR) 2024-08-07 EP disclosed
EP-4406617-A2 COMPOSITION FOR SURFACE MODIFICATION LG Household & Health Care Ltd. (KR) 2024-07-31 EP disclosed
WO-2010146142-A2 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LIMITED (GB) 2010-12-23 WO disclosed
WO-2010056233-A1 COMPOSITION WITH A COLOR TO INDICATE COVERAGE COLGATE-PALMOLIVE COMPANY (US) 2010-05-20 WO disclosed
WO-2010056232-A1 COMPOSITION WITH A COLOR MARKER COLGATE PALMOLIVE COMPANY (US) 2010-05-20 WO disclosed
US-20090269291-A1 Protection of Skin from UV and Peroxide BIODERM RESEARCH (US) 2009-10-29 US disclosed
US-7597879-B2 Sunscreen safety and efficacy enhancement BIODERM RESEARCH (US) 2009-10-06 US disclosed
US-20070189992-A1 Sunscreen Safety and Efficacy Enhancement with Manganese Complexes via Urocanate Pathway BIODERM RESEARCH (US) 2007-08-16 US disclosed
US-20060110415-A1 Topical Delivery System for Cosmetic and Pharmaceutical Agents BIODERM RESEARCH (US) 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12350352-B2 Composition for surface modification CUTA, PTMS, DNMT1 P2RY1 3941/4885P2RY11 3929/4885ENPP1 4396/4885
US-20090269291-A1 Protection of Skin from UV and Peroxide SOD3, UROD, SOD1 P2RY1 2980/4885P2RY11 3588/4885ENPP1 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.